Moderna Shares Up After Product Sales Outlook
January 10 2022 - 12:01PM
Dow Jones News
By Michael Dabaie
Moderna Inc. shares were up 6.7% at $228.27 after the company
said it signed advanced purchase agreements for product sales of
about $18.5 billion.
Moderna says it has signed the agreements for 2022 for about
$18.5 billion, up from the $17 billion it had unveiled in November.
The company added that it signed about $3.5 billion in options,
including for any potential updated Covid-19 vaccine booster
candidates.
Moderna said it is in active talks for additional 2022 Covid-19
vaccine contracts.
The company said 807 millon doses of its Covid vaccine shipped
globally in 2021, with about 25% going to low- and middle-income
countries.
Product sales for 2021 were about $17.5 billion.
"While our Covid-19 vaccine is our first medicine to market, we
have made significant progress across our pipeline of 40
development programs and now have 23 mRNA programs in clinical
trials," Chief Executive Stephane Bancel said in a company
release.
The company said in a presentation at the J.P. Morgan Healthcare
Conference that its product strategy going into 2022 is to bring to
market a pan-respiratory annual booster vaccine, which it will
continuously customize.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 10, 2022 11:46 ET (16:46 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024